NorthWest Biotherapeutics Inc (NWBO)

[ROS-CH]

Saturday's Annual General Meeting does not seem to have been well received, if one considers the reaction on the German trading venues to be relevant.

This is probably mainly due to the statements on the status of the approval procedure, because unfortunately nothing concrete could or would be reported here. According to a transcript from an iHub user, the company does not even seem to know whether this "150-day review process" (which, as described several times, takes much longer than 150 days after an accepted application for approval anyway) is now being used or not. In addition, further queries are expected from the licensing authority.

All in all, unfortunately, new uncertainties and my hopelessly optimistic assessment from the last posting, that one can now expect a decision on the application for approval at any time or that this will be made in the next three or four months, has probably proven to be wrong.

If I interpret the statements now, which, as I said, I only know second-hand from some iHub postings, three to four months of waiting time are more likely to be the best-case scenario and it is more likely to be late autumn or winter before the MHRA decision is likely to be made at the earliest. However, it is more likely that it will not be until next year.

But for the permanent optimists, this development should bring new reason to rejoice, as they can now add to it really cheaply. his is the view of a german NWBO-shareholder :

https://www.wallstreet-online.de/diskussion/1325306-1-10/nwbo-northwest-biotherapeutics-inc-paradigmenwechsel-biotech-phase-3-results#beitrag_76026310


Shareprice in Germany is down 12.5% at the time of this posting.